share_log

Chardan Cuts Price Target on Sonnet BioTherapeutics to $17 From $22, Anticipating Higher Future Share Count, Maintains Buy Rating

Chardan Cuts Price Target on Sonnet BioTherapeutics to $17 From $22, Anticipating Higher Future Share Count, Maintains Buy Rating

查爾丹將Sonnet BioTherapeutics的目標股價從22美元下調至17美元，預計未來股票數量將增加，維持買入評級
MT Newswires ·  2023/04/19 19:23

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

登入免費觀看全文
登入/註冊

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論